Mayo Clinic: Lymphoma, T-Cell trials

The registry lists 12 Lymphoma, T-Cell studies with Mayo Clinic as lead sponsor. 3 are open to participants now and 6 have results posted.

Phase 1 8Phase 2 5No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Q702 for the Treatment of Patients With Hematologic MalignanciesRecruitingNCT06712810Phase 1
• Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaRecruitingNCT06508463Phase 1
• A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingNCT03017820Phase 1
• Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell LymphomaTerminatedNCT03075553Phase 2Results posted
• Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin LymphomaCompletedNCT03035331Phase 1/2Results posted
• Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01261247Phase 2Results posted
• Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT01075321Phase 1/2Results posted
• Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin LymphomaCompletedNCT00918333Phase 1/2Results posted
• Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's LymphomaCompletedNCT00438802Phase 1Results posted
• Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerTerminatedNCT03432741Phase 1
• Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaCompletedNCT02652715Not applicable
• Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D InsufficiencyActive, not recruitingNCT01787409Not applicable